Kai Lovis

USPTO Granted Patents = 12 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 15)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Dusseldorf, DE (2022)
Düsseldorf, DE (2018 - 2024)

Company Filing History:

9 out of 378

Bayer Pharma Aktiengesellschaft

patents

9 out of 12,157

Bayer Aktiengesellschaft

patents

1 out of 1

Bayer Pharma Aktiengsellschaft

patent

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448381 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters (2025-10-21),

2. 12398144 - Photochemical process for producing (4R,4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide (2025-08-26),

3. 12365679 - Process for producing acyloxymethyl esters of (4S)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid (2025-07-22),

4. 12358877 - Synthesis of 4-amino-5-methyl-1H-pyridin-2(1H)-on (intermediate compound for the synthesis of the MR antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine (2025-07-15),

5. 12054481 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters (2024-08-06),

6. 11344519 - Orally administrable modified-release pharmaceutical dosage form (2022-05-31),

7. 11332435 - Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient (2022-05-17),

8. 10905667 - Orally administrable modified-release pharmaceutical dosage form (2021-02-02),

9. 10494372 - Synthesis of copanlisib and its dihydrochloride salt (2019-12-03),

10. 10035803 - Synthesis of copanlisib and its dihydrochloride salt (2018-07-31),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, allow me to assist you with the article about inventor Kai Lovis from Düsseldorf, DE.

Title: Unveiling the Innovative Mind of Kai Lovis: A Pioneering Woman in Inventions

Introduction:

In the realm of inventions, there are trailblazers that shine bright with their creativity and dedication. Kai Lovis, a brilliant inventor hailing from Düsseldorf, DE, stands out with her impressive portfolio of patents and groundbreaking work in pharmaceutical innovations.

Latest Patents:

Kai Lovis has graced the world with her latest patents, showcasing her ingenuity and commitment to advancing pharmaceutical science. One of her notable inventions includes a method for the preparation of a novel compound that holds promising potential in the field of medicine. Additionally, she has developed orally administrable modified-release pharmaceutical dosage forms that aim to revolutionize the treatment and prevention of various diseases.

Career Highlights:

Throughout her career, Kai Lovis has made significant contributions to the pharmaceutical industry. With a total of 6 patents under her belt, she has demonstrated a knack for innovation and a deep understanding of drug development. Her work at Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft has been instrumental in shaping the landscape of pharmaceutical research and development.

Collaborations:

Innovation thrives in collaboration, and Kai Lovis is no stranger to working alongside talented individuals in the field. Among her esteemed coworkers are Philipp Rubenbauer and Heiko Schirmer, who have contributed to her success and the advancement of her inventions. Together, they form a dynamic team dedicated to pushing the boundaries of pharmaceutical innovation.

Conclusion:

In conclusion, Kai Lovis stands as a beacon of innovation and creativity in the world of inventions. Her dedication to developing novel pharmaceutical solutions and her collaborative spirit highlight her as a pioneering woman in the field. With a rich portfolio of patents and a relentless drive for excellence, Kai Lovis continues to inspire future generations of inventors and researchers in shaping a brighter tomorrow in the realm of pharmaceutical sciences.

This text is generated by artificial intelligence and may not be accurate.